BlossomHill Therapeutics, Inc. (BLSM): Results of Operations and Financial Condition
BlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-p
How this was made
The 30-second read
Why it matters
The filing provides the first public disclosure of the Fast Track status, a material regulatory event that can accelerate development timelines and de‑risk the program, likely prompting a short‑term price rally.
Market read
The news is a primary disclosure for a listed biotech, offering a fresh catalyst that could move the stock and influence the oncology sector.
What to watch
The company still reports a net loss of $23.8M and relies on future financing beyond 2028; cash burn remains a risk.
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
The company advanced its clinical and regulatory pipeline and completed an upsized $168.3 million initial public offering, extending its stated cash runway into the second quarter of 2028. However, as a clinical-stage company it reported no revenue, while quarterly net loss widened to $23.8 million from $13.2 million as R&D and G&A expenses increased.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $21.4 million | – | – |
| General and administrative expensesGAAP | $3.3 million | – | – |
| Total operating expensesGAAP | $ 24,670 (in thousands) | – | – |
| Loss from operationsGAAP | $ (24,670 ) (in thousands) | – | – |
| Interest income, netGAAP | $ 915 (in thousands) | – | – |
| Other expense, netGAAP | $ (3 ) (in thousands) | – | – |
| Total other income, netGAAP | $ 912 (in thousands) | – | – |
| Net lossGAAP | $23.8 million | – | – |
| Net loss per share, basic and dilutedGAAP | $(8.75) per basic and diluted share | – | – |
| Weighted average common shares outstanding, basic and dilutedGAAP | 2,713,696 | – | – |
| Six months research and development expensesGAAP | $ 41,256 (in thousands) | – | – |
| Six months general and administrative expensesGAAP | $ 5,521 (in thousands) | – | – |
| Six months total operating expensesGAAP | $ 46,777 (in thousands) | – | – |
| Six months loss from operationsGAAP | $ (46,777 ) (in thousands) | – | – |
| Six months interest income, netGAAP | $ 2,017 (in thousands) | – | – |
| Six months other expense, netGAAP | $ (6 ) (in thousands) | – | – |
| Six months total other income, netGAAP | $ 2,011 (in thousands) | – | – |
| Six months net lossGAAP | $ (44,766 ) (in thousands) | – | – |
| Six months net loss per share, basic and dilutedGAAP | $ (16.91 ) | – | – |
| Six months weighted average common shares outstanding, basic and dilutedGAAP | 2,646,721 | – | – |
| Cash and cash equivalentsGAAP | $95.4 million | – | – |
| Total assetsGAAP | $ 124,131 (in thousands) | – | – |
| Total liabilitiesGAAP | $ 42,088 (in thousands) | – | – |
| Total stockholders’ deficitGAAP | $ (174,780 ) (in thousands) | – | – |
Q4 2026 through 2H 2027 outlook
- NoteBH-30643: Q4 2026: End of Phase 1 meeting regarding a recommended Phase 2 dose selection and a potential accelerated approval pathway in C797S resistance
- NoteBH-30643: Q1 2027: First patient dosed in anticipated pivotal Phase 2 trial
- NoteBH-30643: 1H 2027: Updated Phase 1 data, including C797S durability
- NoteBH-30643: 2H 2027: Updated Phase 1 data on TKI-naive durability and initial chemo combo cohort data
- NoteBH-501284: Q1 2027: Investigational New Drug submission
- NoteBH-30236: 1H 2027: Updated Phase 1 data on safety and anti-leukemic effect
- NoteCash and cash equivalents as of June 30, 2026, together with the proceeds from its IPO, will be sufficient to fund its operations into the second quarter of 2028.
What drove it
- R&D expense increased primarily due to greater clinical development expenses driven by the SOLARA trial, expenses supporting IND-enabling studies for BH-501284, and greater personnel, facilities and other overhead costs.
- G&A expense increased primarily due to greater legal expenses, personnel-related expenses and overhead.
- BH-30643 received FDA Fast Track designation for adult patients with advanced or metastatic EGFR C797S-positive NSCLC after prior treatment with a third-generation EGFR TKI.
- Additional follow-up data presented at IASLC 2026 World Conference on Lung Cancer highlighted a 45% objective response rate and 88% disease control rate in patients with C797S resistance to prior TKIs, with or without concurrent T790M mutation.
- BH-30236 initial clinical data presented at EHA included encouraging safety data and early signs of anti-leukemic activity as monotherapy and in combination with venetoclax.
- BH-501284 preclinical data were presented at AACR 2026. કંપની
Concerns
- The company reported a net loss of $23.8 million, compared with a net loss of $13.2 million for the same period in 2025.
- R&D expenses were $21.4 million, compared with $12.5 million for the same period in 2025.
- G&A expenses were $3.3 million, compared with $1.6 million for the same period in 2025.
- The company is clinical-stage, and no revenue was reported in the filing text.
- Preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials.
- The company disclosed risks around clinical-trial timing, design and enrollment; demonstration of safety and efficacy; regulatory approvals; third-party reliance; and the need for additional financing.
What to watch
- Q4 2026 end-of-Phase 1 meeting for BH-30643, including recommended Phase 2 dose selection and a potential accelerated approval pathway in C797S resistance.
- Q1 2027 anticipated first patient dosed in the pivotal Phase 2 trial for BH-30643.
- Q1 2027 Investigational New Drug submission for BH-501284.
- 1H 2027 updated Phase 1 BH-30643 data, including C797S durability.
- 1H 2027 updated Phase 1 BH-30236 data on safety and anti-leukemic effect.
- 2H 2027 updated BH-30643 Phase 1 data on TKI-naive durability and initial chemo combination cohort data.
- The stated cash runway into the second quarter of 2028.
Balance sheet and cash flow
- Cash and cash equivalents totaled $95.4 million as of June 30, 2026.
- Cash and cash equivalents were $ 136,682 (in thousands) as of December 31, 2025.
- Total current assets were $ 100,968 (in thousands) as of June 30, 2026, compared with $ 138,826 (in thousands) as of December 31, 2025.
- Total assets were $ 124,131 (in thousands) as of June 30, 2026, compared with $ 162,968 (in thousands) as of December 31, 2025.
- Total liabilities were $ 42,088 (in thousands) as of June 30, 2026, compared with $ 37,873 (in thousands) as of December 31, 2025.
- The company sold 10,516,240 shares of common stock, including partial exercise of the over-allotment option, for gross proceeds of $168.3 million in its August 2026 IPO.
- No operating cash flow, free cash flow, or debt balance was reported in the filing text.
Analysis
BlossomHill reported a $23.8 million GAAP net loss for the second quarter of 2026, compared with a $13.2 million net loss in the same period of 2025. Loss per basic and diluted share was $(8.75), compared with $(5.51). The reported operating loss was $24,670 (in thousands), versus $14,103 (in thousands), reflecting heavier program spending rather than commercial activity; the filing text did not report revenue.
R&D was the principal expense driver at $21.4 million, compared with $12.5 million a year earlier. Management attributed the increase to SOLARA clinical development, BH-501284 IND-enabling work, and personnel, facilities and other overhead. G&A rose to $3.3 million from $1.6 million, driven by legal, personnel-related and overhead costs. For the six months ended June 30, R&D was $41,256 (in thousands), total operating expenses were $46,777 (in thousands), and net loss was $44,766 (in thousands).
The quarter's operational progress centered on BH-30643. The company announced FDA Fast Track designation in C797S-positive NSCLC after prior treatment with a third-generation EGFR TKI. It also cited additional follow-up data showing a 45% objective response rate and 88% disease control rate in patients with C797S resistance to prior TKIs, with or without concurrent T790M mutation. BH-30236 data showed encouraging safety data and early signs of anti-leukemic activity, while BH-501284 advanced through preclinical and IND-enabling activities.
Liquidity changed materially after the June 30 balance-sheet date. Cash and cash equivalents were $95.4 million at June 30, 2026, compared with $136,682 (in thousands) at December 31, 2025. In August, the company completed an IPO that generated $168.3 million in gross proceeds through the sale of 10,516,240 shares, including partial exercise of the over-allotment option. The company stated that June 30 cash plus IPO proceeds should fund operations into the second quarter of 2028.
The stated outlook is milestone-based rather than financial. The key near-term event is a Q4 2026 end-of-Phase 1 meeting for BH-30643 concerning Phase 2 dose selection and a potential accelerated approval pathway. Other scheduled items include a Q1 2027 pivotal Phase 2 first-patient dose for BH-30643, a Q1 2027 IND submission for BH-501284, and multiple 2027 clinical updates. The filing provides no revenue, margin, expense, or tax-rate guidance.
Management, verbatim
We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter.
Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics
Not in the filing
stated, not guessed- Revenue and revenue comparisons
- Revenue segments
- Gross profit and gross margin
- GAAP operating margin
- GAAP and non-GAAP income measures other than reported net loss and loss from operations
- Non-GAAP metrics and reconciliations
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balance
- Share repurchases and dividends
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance
- Previous-release outlook for comparison
- Quarter-over-quarter comparisons for reported income-statement metrics
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BlossomHill Therapeutics (Nasdaq:BLSM) filed an 8‑K detailing Q2 2026 financials, an upsized $168.3M IPO, and FDA Fast Track designation for its lead candidate BH‑30643.
Ticker impact
SEC 8‑K reports Q2 2026 results and FDA Fast Track designation for BH‑30643, a new therapy for EGFR C797S‑positive NSCLC.
Potential upside of 10‑15% over the next few weeks as investors price in the Fast Track news and cash balance.
Fast Track designation is a material catalyst for a clinical‑stage biotech; combined with a strong balance sheet from the recent $168M IPO, the market is likely to react favorably.
Market effects
Highlights continued investor interest in EGFR‑targeted therapies and may lift peer biotech stocks in oncology.
Supports broader biotech activity on US exchanges, minimal direct regional effect.
Adds to global pipeline momentum for lung‑cancer treatments, may influence international biotech funding trends.
Counterpoint
If Phase 1 data later underperform expectations, the Fast Track label could be overstated and lead to a pull‑back.
Key entities
- CompanyBlossomHill Therapeutics, Inc.
Clinical‑stage biopharma developing small‑molecule cancer therapies.
- RegulatorFDA
Granted Fast Track designation for BH‑30643.
